Alaunos Therapeutics Announces $2.0 Million Registered Direct Offering

Group 1 - Alaunos Therapeutics, Inc. has entered into a definitive agreement for the purchase and sale of 610,399 shares of common stock at a price of $3.36 per share in a registered direct offering, expected to close on or about June 24, 2025 [1][2]. - The gross proceeds from this offering are anticipated to be approximately $2.0 million, with net proceeds of about $1.9 million intended for the company's obesity program and general corporate purposes [2]. - The offering is being conducted under a shelf registration statement previously filed and declared effective by the U.S. Securities and Exchange Commission [3]. Group 2 - Alaunos is a preclinical stage company focused on developing small molecule-based drugs for obesity and metabolic health, aiming to create a treatment that does not rely on hormonal manipulation, unlike many current therapies [8].